公开(公告)号：US20210244727A1

公开(公告)日：2021-08-12

申请号：US17243177

申请日：2021-04-28

Applicant: FORMA Therapeutics, Inc.

Inventor： Susan ASHWELL ,  Blythe THOMSON ,  Patrick F. KELLY ,  Alan COLLIS ,  Jeff DAVIS ,  Duncan WALKER ,  Wei LU

IPC: A61K31/4709 ,  A61K31/706 ,  A61P35/00 ,  A61P35/02

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

公开(公告)号：US20240148718A1

公开(公告)日：2024-05-09

申请号：US18220779

申请日：2023-07-11

Applicant: FORMA Therapeutics, Inc.

Inventor： Susan ASHWELL ,  Blythe THOMSON ,  Patrick F. KELLY ,  Alan COLLIS ,  Jeff DAVIS ,  Duncan WALKER ,  Wei LU

IPC: A61K31/4709 ,  A61K31/706 ,  A61P35/00 ,  A61P35/02

CPC classification number: A61K31/4709 ,  A61K31/706 ,  A61P35/00 ,  A61P35/02

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.